Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the autonomic nervous system (the part of the nervous system that controls involuntary action such as blood pressure or digestion) and movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. The initial symptoms of MSA are often difficult to distinguish from the initial symptoms of Parkinson’s disease and include: slowness of movement, tremor, or rigidity (stiffness); clumsiness or incoordination; impaired speech, a croaky, quivering voice; fainting or lightheadedness due to orthostatic hypotension; bladder control problems, such as a sudden urge to urinate or difficulty emptying the bladder.
The cause of MSA is unknown. The vast majority of cases are sporadic, meaning they occur at random. A distinguishing feature of MSA is the accumulation of the protein alpha-synuclein in glia, the cells that support nerve cells in the brain. These deposits of alpha-synuclein particularly occur in oligodendroglia. This protein also accumulates in Parkinson’s disease, but in nerve cells. Because they both have a buildup of alpha-synuclein in cells, MSA and Parkinson’s disease are sometimes referred to as synucleinopathies.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market
The Multiple System Atrophy market report also covers emerging drugs, current treatment practices, Multiple System Atrophy market share of the individual therapies, current and forecasted Multiple System Atrophy Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Multiple System Atrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Multiple System Atrophy Market Key Facts
As per the National Organization for Rare Disorders, MSA appears to affect males and females in equal numbers. The peak onset of MSA is between 55-60 years of age, with a range from 30 to over 90 years.
According to the “National Institute of Neurological Disorders and Stroke”, MSA is a rare disease, affecting potentially 15,000 to 50,000 Americans, including men and women and all racial groups.
Key Benefits of Multiple System Atrophy Market Report
-
Multiple System Atrophy market report provides an in-depth analysis of Multiple System Atrophy Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Multiple System Atrophy market report will help in developing business strategies by understanding the Multiple System Atrophy Market trends & developments, key players and future market competition that will shape and drive the Multiple System Atrophy market in the upcoming years.
-
The Multiple System Atrophy market report covers Multiple System Atrophy current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Multiple System Atrophy market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Multiple System Atrophy Market
The Multiple System Atrophy market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Multiple System Atrophy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Multiple System Atrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The dynamics of the Multiple System Atrophy market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period of 2020–2030.
Multiple System Atrophy Epidemiology
Multiple system atrophy (MSA) is a rare neurodegenerative disorder that presents with a variable combination of autonomic, cerebellar, parkinsonian and pyramidal features . MSA is an orphan disease with an incidence of up to 2.4 cases per 100 000 persons per year, while the prevalence may reach up to 7.8 patients per 100 000 population over the age of 40.
The Multiple System Atrophy epidemiology section covers insights about historical and current Multiple System Atrophy patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Multiple System Atrophy Drugs Uptake and Key Market Players
The Multiple System Atrophy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple System Atrophy market or expected to get launched in the market during the study period. The analysis covers Multiple System Atrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
There are no treatments available to slow down or stop the progression of MSA. Currently, available treatments are symptomatic and include medications to treat parkinsonian symptoms, orthostatic hypotension, urinary symptoms, and sexual dysfunction. Patients typically get brief and modest responses to these limited arsenals of medications. Some of the key players actively working toward the development of potential therapies in order to fulfill the unmet medical needs in the Multiple System Atrophy market includes:
Theravance Biopharma
Biohaven Pharmaceutical
Biogen
Zambon
Corestem
Alterity Therapeutics
And many others
Drugs Covered
Ampreloxetine/TD-9855
BHV-3241
BIIB101
Safinamide
CS10BR05
ATH434
And many others
Table of Content
1. Key Insights
2. Executive Summary
3. Multiple System Atrophy Competitive Intelligence Analysis
4. Multiple System Atrophy Market Overview at a Glance
5. Multiple System Atrophy Disease Background and Overview
6. Multiple System Atrophy Patient Journey
7. Multiple System Atrophy Epidemiology and Patient Population
8. Multiple System Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Multiple System Atrophy Unmet Needs
10. Key Endpoints of Multiple System Atrophy Treatment
11. Multiple System Atrophy Marketed Products
12. Multiple System Atrophy Emerging Therapies
13. Multiple System Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Multiple System Atrophy Market Outlook (7 major markets)
16. Multiple System Atrophy Access and Reimbursement Overview
17. KOL Views on the Multiple System Atrophy Market.
18. Multiple System Atrophy Market Drivers
19. Multiple System Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Multiple System Atrophy (MSA) Epidemiology Forecast to 2030
DelveInsight’s Multiple System Atrophy (MSA) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Multiple System Atrophy (MSA) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Multiple System Atrophy (MSA) Pipeline Insights, 2020
Multiple System Atrophy (MSA) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Multiple System Atrophy (MSA) market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/